Should I Buy RPRX? RPRX 2026 Analysis

Should You Buy Royalty Pharma PLC (RPRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

44.100

1 Day change

0.96%

52 Week Range

44.350

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BUY now. RPRX is in a clear uptrend (bullish MA stack and rising MACD), sentiment from options is strongly bullish (very low put/call), and Wall Street targets ($49–$50) imply ~18%–21% upside from $41.44. With hedge funds notably increasing buying and an earnings catalyst (2025 Q4) coming on 2026-02-11, the setup favors owning shares now rather than waiting for a perfect pullback—despite the stock looking a bit stretched short-term (RSI ~72) and sitting near resistance.

Technical Analysis

Trend/price action: Bullish. Moving averages are positively aligned (SMA_5 > SMA_20 > SMA_200), which typically signals sustained upside momentum. MACD histogram is positive (0.079) and expanding, reinforcing the uptrend.

Overbought/entry timing: RSI_6 is ~72.4, which is elevated and often associated with short-term “overbought” conditions—this doesn’t negate the uptrend, but it does raise the odds of brief pauses or dips.

Levels: Pivot ~40.16 is the key near-term line to hold for bulls. Price ($41.44) is above R1 (41.11) and approaching R2 (41.70). A clean hold above ~41.11 supports continuation; a break above ~41.70 would be the next technical confirmation of another leg higher.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Strongly bullish positioning. Open interest put/call at 0.25 and volume put/call at 0.15 indicates calls dominate puts (traders leaning bullish).

Activity/volatility: Implied volatility (30D) is elevated at ~43.5 with IV percentile ~80, meaning options are pricing a larger-than-usual move versus most of the past year. Today’s volume vs 30D average is extremely high (21.98x), suggesting event/positioning intensity (often consistent with an upcoming catalyst like earnings).

Interpretation: Options market is positioned for upside, but the elevated IV implies the market expects a meaningful move (and options are relatively expensive).

Technical Summary

Sell

Buy

Positive Catalysts

- Analyst momentum: Multiple bullish updates with targets lifted into the $45–$50 range; UBS upgrade to Buy with $49 target highlights “catalyst-rich” 2026 and growth from new royalty deals.
- Hedge fund flow: “Hedge Funds are Buying,” with buying amount up ~100.83% over the last quarter.
- Upcoming catalyst: Earnings for 2025 Q4 on 2026-02-11 (pre-market). With heightened options activity, the market appears to be positioning ahead of this event.
- Technical momentum: Bullish MA stack + positive, expanding MACD supports trend continuation.

Neutral/Negative Catalysts

can swing the stock either way.

Financial Performance

Latest quarter provided: 2025/Q3.

Revenue: $609.3M, +7.9% YoY (positive top-line growth trend).
Net income: $288.2M, -47.0% YoY (material decline).
EPS: $0.67, -44.6% YoY (profitability pressure).
Gross margin: Listed at 100 (royalty model can show very high gross margin); the key concern in the snapshot is the YoY drop in earnings power despite higher revenue.

Overall: Growth on revenue is constructive, but the earnings decline is the main fundamental blemish heading into the 2025 Q4 print.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Net positive.

2026-01-30: UBS upgraded to Buy (from Neutral) and raised PT to $49 (from $38), citing attractive royalty deals and multiple 2026 catalysts.
2026-01-27: Citi reiterated Buy and raised PT to $50 (from $48).
2025-12-11: TD Cowen reiterated Buy and raised PT to $45 (from $42).

Wall Street pros view (bull case): Royalty deal pipeline improves growth profile; multiple de-risking/catalyst events expected; viewed favorably vs large-cap pharma facing LOE headwinds.

Wall Street cons view (bear case): Earnings power can be uneven quarter-to-quarter (as seen in the latest YoY net income/EPS drop). Also, one provided note mentions an acquisition at ~$1.82/share (2025-11-17), which is inconsistent with the current ~$41 price—this appears to be a data anomaly and should not be relied upon.

Influential/political trading: No recent congress trading data available; insiders are neutral with no significant recent trend.

2 Analyst Rating

Wall Street analysts forecast RPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPRX is 46.5 USD with a low forecast of 45 USD and a high forecast of 48 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 43.680

Low

Averages

46.5

High

Current: 43.680

Low

Averages

46.5

High

UBS

Ashwani Verma

Neutral -> Buy

upgrade

$38 -> $49

AI Analysis

2026-01-30

Reason

UBS

Ashwani Verma

Price Target

$38 -> $49

AI Analysis

2026-01-30

upgrade

Neutral -> Buy

Reason

UBS analyst Ashwani Verma upgraded Royalty Pharma to Buy from Neutral with a price target of $49, up from $38. The company has done a series of attractive royalty deals, which boosts its growth profile "meaningfully," the analyst tells investors in a research note. The firm sees a "catalyst-rich" 2026 for Royalty that can drive "significant stock upside on upcoming de-risking events." The company's growth profile is attractive on both an absolute and relative basis versus a number of large-cap pharma names that are facing material loss of exclusivities, contends UBS.

Citi

Buy

maintain

$48 -> $50

2026-01-27

Reason

Citi

Price Target

$48 -> $50

2026-01-27

maintain

Buy

Reason

Citi raised the firm's price target on Royalty Pharma to $50 from $48 and keeps a Buy rating on the shares. The firm adjusted targets in the biopharma group as part of a Q4 preview. Estimates that are "beatable" and lower policy risk should create a favorable setup in 2026 for the group, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RPRX

Unlock Now

RPRX Should I Buy

RPRX Should I Buy

Should You Buy Royalty Pharma PLC (RPRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch